Taro Pharm Inds (TARO) 145.59 $TARO
Bullish Two Hundred Day Moving Average Cross - TARO
MarketNewsVideo.com - Fri Apr 10, 3:35PM CDT
In trading on Friday, shares of Taro Pharmaceutical Industries Ltd. crossed above their 200 day moving average of $149.55, changing hands as high as $149.76 per share.
TARO: 145.59 (-0.71)
Mylan makes $205/share bid for Perrigo; Generic firms rally
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 10:47AM CDT
IPXL: 49.55 (-0.53), MNK: 122.01 (-2.84), LCI: 67.40 (unch), PRGO: 192.89 (-8.74), TARO: 145.59 (-0.71), AKRX: 55.24 (-0.68), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16)
March 'Midness' - Which Mid-Cap Stock Will Come Out On Top? Part 2
Alexandra Reisman - Seeking Alpha - Sun Apr 05, 3:07AM CDT
Hello mid cap stock fans! Last week, I posted the results of the first two rounds of my March 'Midness' tournament that I've been running over on the Stock Rover Blog. Now for the final three rounds, focusing on efficiency, competitive advantage,...
1 Comment
CNC: 73.67 (+1.13), TARO: 145.59 (-0.71), OTEX: 55.83 (-1.58), TYL: 132.12 (+1.82), GNTX: 17.94 (-0.18), MMS: 67.16 (-0.55), PII: 141.59 (-5.11)
3 Cheap Growth Stocks You Can Buy Right Now
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 26, 7:04AM CDT
Source: Flickr user Frankleleon. With the stock market in nearly nonstop rally mode over the past five years, investors haven't needed to look far to uncover an abundance of growth stocks. But not all growth stocks are created equal. While some...
TARO: 145.59 (-0.71), AFOP: 19.33 (-0.43), SWHC: 15.01 (+0.10)
March 'Midness' - Which Mid-Cap Stock Will Come Out On Top?
Alexandra Reisman - at Seeking Alpha - Tue Mar 24, 5:34AM CDT
We at Stock Rover are excited about the NCAA Division I "March Madness" Basketball tournament this month, so in honor of the event we thought we'd run a single-elimination style tournament of our own. Stock Rover has never been very good at...
LAD: 107.06 (+2.15), DFT: 32.69 (+0.41), TARO: 145.59 (-0.71), OTEX: 55.83 (-1.58), UTHR: 186.69 (-1.87), TYL: 132.12 (+1.82), LHO: 38.40 (-0.10), GNTX: 17.94 (-0.18), MMS: 67.16 (-0.55), PII: 141.59 (-5.11)
Ontario to See $3.66 Billion in Project Construction Starts in Second-Quarter 2015, Fueled by Natural Gas, Wind Power, an Industrial Info News Alert
Marketwired - Wed Mar 18, 5:00AM CDT
Researched by Industrial Info Resources (Sugar Land, Texas) -- Ontario's Power Industry is the driving force behind $3.66 billion in projects expected to kick off in Canadian province in the second quarter of 2015. More than half of that amount is attributed to projects fueled by natural gas and wind power, according to Industrial Info's project database, and all but $150 million of the total can be found in four industries: Power, Metals & Minerals, Pharmaceutical & Biotech, and Food & Beverage.
NGD.TO: 3.89 (-0.10), TARO: 145.59 (-0.71), TRP: 47.13 (+0.12), NGD: 3.20 (-0.10)
Irish Highlanders: Drug Stocks Mallinckrodt, Horizon Pharma Rally
at Investor's Business Daily - Thu Mar 05, 5:32PM CST
Drugmakers seized market headlines Thursday when Pharmacyclics (PCYC) spiked 10% on word that it would be acquired by AbbVie (ABBV) in a $21 billion cash and stock deal. The news sent AbbVie down 5% in heavy trade, but also launched a mild rally...
MNK: 122.01 (-2.84), PCYC: 256.59 (-0.51), TARO: 145.59 (-0.71), HZNP: 31.75 (+0.97), ABBV: 66.07 (+1.82), ICLR: 69.85 (+0.44)
Beating The Little Book That Beats The Market
Kyle Pinkerton - at Seeking Alpha - Tue Feb 24, 10:41AM CST
SAFM: 76.06 (-0.23), WMT: 79.84 (+0.66), USNA: 128.29 (+0.17), INTC: 32.08 (-0.27), LYB: 100.83 (+3.26), OCIR: 24.48 (+0.01), TSRA: 38.40 (-1.17), DTV: 89.85 (-0.27), MSFT: 47.87 (+4.53), DLX: 67.37 (-0.17), AAPL: 130.28 (+0.61), HRB: 32.26 (-0.38), KO: 40.89 (-0.06), WLK: 77.05 (+1.08), NTES: 122.19 (+3.26), MAN: 85.15 (+1.51), WNR: 47.03 (+1.27), ALK: 68.30 (+1.96), CMP: 88.45 (-0.73), PM: 82.75 (-0.80), HCA: 77.74 (+0.30), BBBY: 72.53 (-0.27), CALM: 41.00 (+0.25), TJX: 66.29 (-0.04), AZO: 702.00 (-0.33), GILD: 103.69 (-1.52), TARO: 145.59 (-0.71), PINC: 38.00 (+0.01), NTL: 21.64 (+0.16)
Taro Pharma ups EPS 29% in FQ3
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 9:24AM CST
TARO: 145.59 (-0.71)
Taro posts better operating income of USD159.3m for quarter ended 31 December 2014
M2 - Wed Feb 11, 5:18AM CST
Pharmaceutical company Taro Pharmaceutical Industries (NYSE:TARO) disclosed on Tuesday that it recorded operating income of USD159.3m, or 67.0% of net sales, for the three months ended 31 December 2014.
TARO: 145.59 (-0.71)
Taro Pharmaceutical reports FQ3 earnings
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 3:51PM CST
TARO: 145.59 (-0.71)
Taro Provides Results for December 31, 2014
Business Wire - Tue Feb 10, 3:25PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"
today provided unaudited financial results for the three months and nine months ended December 31, 2014.
TARO: 145.59 (-0.71)
Pfizer Pays A Pretty Penny For Hospira: Here's What You Need To Know
Brendan O'Boyle - at Seeking Alpha - Tue Feb 10, 8:49AM CST
ABT: 48.32 (-0.14), TARO: 145.59 (-0.71), PFE: 35.27 (-0.09), MYL: 76.06 (+2.37), EPRS: 8.67 (-0.10), TEVA: 64.41 (+1.16), HSP: 87.61 (-0.05)
Taro to Announce Third Quarter Results on February 10, 2015
Business Wire - Thu Feb 05, 3:07PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2014, after the close of market on Tuesday, February 10, 2015.
TARO: 145.59 (-0.71)
Spirit Air, Other Leading Stocks Shaping New Bases
at Investor's Business Daily - Thu Jan 29, 5:04PM CST
A number of top stocks in Your Weekly Review are working on bases, as strong jobs data boosted the major averages Thursday. Still, the market's uptrend remains under pressure, which adds risk to new purchases. Investors should consider buying only...
SAVE: 77.42 (+0.43), CSTE: 60.04 (+0.54), TARO: 145.59 (-0.71), APOG: 53.48 (+0.55), FRGI: 54.90 (-4.19)
Dermatitis Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014-2015
M2 - Fri Jan 16, 5:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/449cq9/dermatitis_market) has announced the addition of the "Dermatitis Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Dermatitis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Allergan, Inc. - Astellas Pharma US, Inc. - Horizon Pharma, Inc. - Quinnova Pharmaceuticals, Inc. - Merck & Co., Inc. - Bayer HealthCare Pharmaceuticals Inc. - Stiefel Laboratories, Inc. - AbbVie Inc. - Pfizer Inc. - Pharmacia & Upjohn, Inc. - Roxane Laboratories, Inc. - PharmaDerm - Prestium Pharma, Inc. - Aqua Pharmaceuticals, LLC - Lilly USA, LLC - Novartis Pharmaceuticals Corporation - Astellas Pharma Inc. - Organon USA Inc. - Apothecon Inc - Schering-Plough HealthCare Products, Inc - Schering-Plough Corporation (Inactive) - Taro Pharmaceutical Industries Ltd. - Merck Sharp & Dohme Corp. - Onset Dermatologics - Standard Homeopathic Company - Sandoz Inc. - Panray Corporation - UCB, Inc. - Concordia Pharmaceuticals Inc. - Medimetriks Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/44...tis_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AGN: 240.22 (+2.88), TARO: 145.59 (-0.71), PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), HZNP: 31.75 (+0.97), ABBV: 66.07 (+1.82), NVS: 104.28 (-1.22)
3 Reasons To Be Bullish On Generic Drug Firm Akorn
at Investor's Business Daily - Thu Jan 15, 1:12PM CST
With a top IBD Composite Rating of 99 and four straight quarters of accelerated EPS growth, generic drug maker Akorn (AKRX) is already doing pretty well. A new analyst report outlines even more reasons to be bullish on the stock for 2015. Lake...
ACT: 295.41 (-2.95), VRX: 210.42 (+1.03), TARO: 145.59 (-0.71), AKRX: 55.24 (-0.68), MYL: 76.06 (+2.37), NVS: 104.28 (-1.22)
Taro Announces Results of Its Annual General Meeting of Shareholders
Business Wire - Wed Dec 24, 12:30PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company" announced that the Company held its annual general meeting of shareholders on December 22, 2014, at the offices of Meitar Liquornik Geva Leshem Tal, located at 16 Abba Hillel Road, Gallery Floor, Ramat Gan (the "Annual General Meeting" .
TARO: 145.59 (-0.71)
Stock Movers: Why 4 Big Drug Stocks Are Rising Today
at Investor's Business Daily - Tue Nov 18, 1:38PM CST
Drugmakers clustered near the top of IBD's Stocks On The Move list Tuesday afternoon. Actavis (ACT), an Ireland-based maker of generic and branded drugs, shot up more than 7% in huge volume in Tuesday afternoon trading on the stock market today. That...
AGN: 240.22 (+2.88), VRX: 210.42 (+1.03), ACT: 295.41 (-2.95), TARO: 145.59 (-0.71), GILD: 103.69 (-1.52)
Taro Pharmaceutical Industries' (TARO) CEO Kal Sundaram on Q2 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 2:07PM CST
TARO: 145.59 (-0.71)
Bullish Two Hundred Day Moving Average Cross - TARO
MarketNewsVideo.com - Fri Apr 10, 3:35PM CDT
In trading on Friday, shares of Taro Pharmaceutical Industries Ltd. crossed above their 200 day moving average of $149.55, changing hands as high as $149.76 per share.
TARO: 145.59 (-0.71)
Mylan makes $205/share bid for Perrigo; Generic firms rally
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 10:47AM CDT
IPXL: 49.55 (-0.53), MNK: 122.01 (-2.84), LCI: 67.40 (unch), PRGO: 192.89 (-8.74), TARO: 145.59 (-0.71), AKRX: 55.24 (-0.68), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16)
March 'Midness' - Which Mid-Cap Stock Will Come Out On Top? Part 2
Alexandra Reisman - Seeking Alpha - Sun Apr 05, 3:07AM CDT
Hello mid cap stock fans! Last week, I posted the results of the first two rounds of my March 'Midness' tournament that I've been running over on the Stock Rover Blog. Now for the final three rounds, focusing on efficiency, competitive advantage,...
1 Comment
CNC: 73.67 (+1.13), TARO: 145.59 (-0.71), OTEX: 55.83 (-1.58), TYL: 132.12 (+1.82), GNTX: 17.94 (-0.18), MMS: 67.16 (-0.55), PII: 141.59 (-5.11)
3 Cheap Growth Stocks You Can Buy Right Now
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 26, 7:04AM CDT
Source: Flickr user Frankleleon. With the stock market in nearly nonstop rally mode over the past five years, investors haven't needed to look far to uncover an abundance of growth stocks. But not all growth stocks are created equal. While some...
TARO: 145.59 (-0.71), AFOP: 19.33 (-0.43), SWHC: 15.01 (+0.10)
March 'Midness' - Which Mid-Cap Stock Will Come Out On Top?
Alexandra Reisman - at Seeking Alpha - Tue Mar 24, 5:34AM CDT
We at Stock Rover are excited about the NCAA Division I "March Madness" Basketball tournament this month, so in honor of the event we thought we'd run a single-elimination style tournament of our own. Stock Rover has never been very good at...
LAD: 107.06 (+2.15), DFT: 32.69 (+0.41), TARO: 145.59 (-0.71), OTEX: 55.83 (-1.58), UTHR: 186.69 (-1.87), TYL: 132.12 (+1.82), LHO: 38.40 (-0.10), GNTX: 17.94 (-0.18), MMS: 67.16 (-0.55), PII: 141.59 (-5.11)
Ontario to See $3.66 Billion in Project Construction Starts in Second-Quarter 2015, Fueled by Natural Gas, Wind Power, an Industrial Info News Alert
Marketwired - Wed Mar 18, 5:00AM CDT
Researched by Industrial Info Resources (Sugar Land, Texas) -- Ontario's Power Industry is the driving force behind $3.66 billion in projects expected to kick off in Canadian province in the second quarter of 2015. More than half of that amount is attributed to projects fueled by natural gas and wind power, according to Industrial Info's project database, and all but $150 million of the total can be found in four industries: Power, Metals & Minerals, Pharmaceutical & Biotech, and Food & Beverage.
NGD.TO: 3.89 (-0.10), TARO: 145.59 (-0.71), TRP: 47.13 (+0.12), NGD: 3.20 (-0.10)
Irish Highlanders: Drug Stocks Mallinckrodt, Horizon Pharma Rally
at Investor's Business Daily - Thu Mar 05, 5:32PM CST
Drugmakers seized market headlines Thursday when Pharmacyclics (PCYC) spiked 10% on word that it would be acquired by AbbVie (ABBV) in a $21 billion cash and stock deal. The news sent AbbVie down 5% in heavy trade, but also launched a mild rally...
MNK: 122.01 (-2.84), PCYC: 256.59 (-0.51), TARO: 145.59 (-0.71), HZNP: 31.75 (+0.97), ABBV: 66.07 (+1.82), ICLR: 69.85 (+0.44)
Beating The Little Book That Beats The Market
Kyle Pinkerton - at Seeking Alpha - Tue Feb 24, 10:41AM CST
SAFM: 76.06 (-0.23), WMT: 79.84 (+0.66), USNA: 128.29 (+0.17), INTC: 32.08 (-0.27), LYB: 100.83 (+3.26), OCIR: 24.48 (+0.01), TSRA: 38.40 (-1.17), DTV: 89.85 (-0.27), MSFT: 47.87 (+4.53), DLX: 67.37 (-0.17), AAPL: 130.28 (+0.61), HRB: 32.26 (-0.38), KO: 40.89 (-0.06), WLK: 77.05 (+1.08), NTES: 122.19 (+3.26), MAN: 85.15 (+1.51), WNR: 47.03 (+1.27), ALK: 68.30 (+1.96), CMP: 88.45 (-0.73), PM: 82.75 (-0.80), HCA: 77.74 (+0.30), BBBY: 72.53 (-0.27), CALM: 41.00 (+0.25), TJX: 66.29 (-0.04), AZO: 702.00 (-0.33), GILD: 103.69 (-1.52), TARO: 145.59 (-0.71), PINC: 38.00 (+0.01), NTL: 21.64 (+0.16)
Taro Pharma ups EPS 29% in FQ3
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 9:24AM CST
TARO: 145.59 (-0.71)
Taro posts better operating income of USD159.3m for quarter ended 31 December 2014
M2 - Wed Feb 11, 5:18AM CST
Pharmaceutical company Taro Pharmaceutical Industries (NYSE:TARO) disclosed on Tuesday that it recorded operating income of USD159.3m, or 67.0% of net sales, for the three months ended 31 December 2014.
TARO: 145.59 (-0.71)
Taro Pharmaceutical reports FQ3 earnings
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 3:51PM CST
TARO: 145.59 (-0.71)
Taro Provides Results for December 31, 2014
Business Wire - Tue Feb 10, 3:25PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"
today provided unaudited financial results for the three months and nine months ended December 31, 2014. TARO: 145.59 (-0.71)
Pfizer Pays A Pretty Penny For Hospira: Here's What You Need To Know
Brendan O'Boyle - at Seeking Alpha - Tue Feb 10, 8:49AM CST
ABT: 48.32 (-0.14), TARO: 145.59 (-0.71), PFE: 35.27 (-0.09), MYL: 76.06 (+2.37), EPRS: 8.67 (-0.10), TEVA: 64.41 (+1.16), HSP: 87.61 (-0.05)
Taro to Announce Third Quarter Results on February 10, 2015
Business Wire - Thu Feb 05, 3:07PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2014, after the close of market on Tuesday, February 10, 2015.
TARO: 145.59 (-0.71)
Spirit Air, Other Leading Stocks Shaping New Bases
at Investor's Business Daily - Thu Jan 29, 5:04PM CST
A number of top stocks in Your Weekly Review are working on bases, as strong jobs data boosted the major averages Thursday. Still, the market's uptrend remains under pressure, which adds risk to new purchases. Investors should consider buying only...
SAVE: 77.42 (+0.43), CSTE: 60.04 (+0.54), TARO: 145.59 (-0.71), APOG: 53.48 (+0.55), FRGI: 54.90 (-4.19)
Dermatitis Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014-2015
M2 - Fri Jan 16, 5:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/449cq9/dermatitis_market) has announced the addition of the "Dermatitis Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Dermatitis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Allergan, Inc. - Astellas Pharma US, Inc. - Horizon Pharma, Inc. - Quinnova Pharmaceuticals, Inc. - Merck & Co., Inc. - Bayer HealthCare Pharmaceuticals Inc. - Stiefel Laboratories, Inc. - AbbVie Inc. - Pfizer Inc. - Pharmacia & Upjohn, Inc. - Roxane Laboratories, Inc. - PharmaDerm - Prestium Pharma, Inc. - Aqua Pharmaceuticals, LLC - Lilly USA, LLC - Novartis Pharmaceuticals Corporation - Astellas Pharma Inc. - Organon USA Inc. - Apothecon Inc - Schering-Plough HealthCare Products, Inc - Schering-Plough Corporation (Inactive) - Taro Pharmaceutical Industries Ltd. - Merck Sharp & Dohme Corp. - Onset Dermatologics - Standard Homeopathic Company - Sandoz Inc. - Panray Corporation - UCB, Inc. - Concordia Pharmaceuticals Inc. - Medimetriks Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/44...tis_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AGN: 240.22 (+2.88), TARO: 145.59 (-0.71), PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), HZNP: 31.75 (+0.97), ABBV: 66.07 (+1.82), NVS: 104.28 (-1.22)
3 Reasons To Be Bullish On Generic Drug Firm Akorn
at Investor's Business Daily - Thu Jan 15, 1:12PM CST
With a top IBD Composite Rating of 99 and four straight quarters of accelerated EPS growth, generic drug maker Akorn (AKRX) is already doing pretty well. A new analyst report outlines even more reasons to be bullish on the stock for 2015. Lake...
ACT: 295.41 (-2.95), VRX: 210.42 (+1.03), TARO: 145.59 (-0.71), AKRX: 55.24 (-0.68), MYL: 76.06 (+2.37), NVS: 104.28 (-1.22)
Taro Announces Results of Its Annual General Meeting of Shareholders
Business Wire - Wed Dec 24, 12:30PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"
announced that the Company held its annual general meeting of shareholders on December 22, 2014, at the offices of Meitar Liquornik Geva Leshem Tal, located at 16 Abba Hillel Road, Gallery Floor, Ramat Gan (the "Annual General Meeting" . TARO: 145.59 (-0.71)
Stock Movers: Why 4 Big Drug Stocks Are Rising Today
at Investor's Business Daily - Tue Nov 18, 1:38PM CST
Drugmakers clustered near the top of IBD's Stocks On The Move list Tuesday afternoon. Actavis (ACT), an Ireland-based maker of generic and branded drugs, shot up more than 7% in huge volume in Tuesday afternoon trading on the stock market today. That...
AGN: 240.22 (+2.88), VRX: 210.42 (+1.03), ACT: 295.41 (-2.95), TARO: 145.59 (-0.71), GILD: 103.69 (-1.52)
Taro Pharmaceutical Industries' (TARO) CEO Kal Sundaram on Q2 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 2:07PM CST
TARO: 145.59 (-0.71)
